Recent advances in targeted therapy of primary IgA nephropathy

IgA nephropathy(IgAN) has become a major disease threatening the quality-of-life of Chinese residents.Currently the treatment of this disease is mainly supportive and immunosuppressive therapy.Immunosuppressive therapy is associated with many side effects.Therefore the selectivity and safety of drugs are essential for treating IgAN.Based on the continuous understanding of autoimmune pathogenesis of IgAN, many targets are available for drug therapy, including immune response, mucosal immunity, renal inflammation and complement activation.Based on the pathogenesis of IgAN, this review summarized the latest advances of IgAN targeted therapy.